Keyhole limpet hemocyanin potentiates standard immunotherapy for melanoma.

Article Details

Citation

McFadden DW, Riggs DR, Jackson BJ, Ng A, Cunningham C

Keyhole limpet hemocyanin potentiates standard immunotherapy for melanoma.

Am J Surg. 2007 Feb;193(2):284-7.

PubMed ID
17236863 [ View in PubMed
]
Abstract

INTRODUCTION: Our hypothesis was that keyhole limpet hemocyanin (KLH) would augment the effects of standard immunotherapies for melanoma including interferon-alpha (AIFN) and interleukin (IL)-2. METHODS: The HTB68 melanoma cell line was treated with KLH, AIFN, and IL-2 as single and combined agents. Cell viability, apoptotic activity, and vascular endothelial growth factor levels were all evaluated. RESULTS: Cell growth was reduced with KLH (28%), AIFN (54%), and IL-2 (29%) (all P < .001). KLH and IL-2 combined exhibited a 47% inhibition of cell growth, whereas KLH and AIFN combined yielded a 67% reduction in cell growth (both P < .001). KLH and AIFN combined significantly increased both early (10%) and late (14%) apoptotic activity compared with controls (5% and 7%, P < .001). CONCLUSIONS: The additive effects exhibited by the combination of KLH with AIFN or IL-2 are encouraging and support combination therapy as an effective treatment for this aggressive disease.

DrugBank Data that Cites this Article

Drugs